PURPOSE: The purpose of this study was to cross-sectionally assess quality of life (QoL) in survivors of childhood Hodgkin's disease (HD) in a cohort treated for HD in the successive German-Austrian therapy studies HD-78, HD-82, HD-85, HD-87, HD-90, HD-95, respectively, in accordance with the HD-Interval-Treatment recommendation between 1978 and 2002. PATIENTS AND METHODS: Data from QoL questionnaires were provided by 1,202 (66 %) of 1,819 invited survivors. These included the EORTC QLQ-C30 and socio-demographic variables. Data of a homogenous sub-sample (n = 725) defined by age (21-41 years) and event- free-survival (no progress, relapse or secondary malignancies) were compared to an age-adjusted German reference sample (n = 659). RESULTS: While the global and physical QoL scores were comparable to those of the general population, survivors' mean scores were more than 10 points lower on the EORTC QLQ-C30 scales "Emotional" and "Social Functioning". On the symptom scales, higher mean scores, exceeding 10 points, were obtained for the scales "Fatigue" and "Sleep". In general, there was a gender effect showing lower functioning and higher symptom levels in women, most prominently in the group of young women (21-25 years). The results within the group of HD survivors could not be associated with the time since treatment, the age of HD survivors at diagnosis or the extent of therapy burden. CONCLUSION: Clinicians engaged in follow-up care should be sensitive to aspects of fatigue and related (emotional) symptoms in HD childhood cancer survivors and encourage their patients to seek further support if needed.
PURPOSE: The purpose of this study was to cross-sectionally assess quality of life (QoL) in survivors of childhood Hodgkin's disease (HD) in a cohort treated for HD in the successive German-Austrian therapy studies HD-78, HD-82, HD-85, HD-87, HD-90, HD-95, respectively, in accordance with the HD-Interval-Treatment recommendation between 1978 and 2002. PATIENTS AND METHODS: Data from QoL questionnaires were provided by 1,202 (66 %) of 1,819 invited survivors. These included the EORTC QLQ-C30 and socio-demographic variables. Data of a homogenous sub-sample (n = 725) defined by age (21-41 years) and event- free-survival (no progress, relapse or secondary malignancies) were compared to an age-adjusted German reference sample (n = 659). RESULTS: While the global and physical QoL scores were comparable to those of the general population, survivors' mean scores were more than 10 points lower on the EORTC QLQ-C30 scales "Emotional" and "Social Functioning". On the symptom scales, higher mean scores, exceeding 10 points, were obtained for the scales "Fatigue" and "Sleep". In general, there was a gender effect showing lower functioning and higher symptom levels in women, most prominently in the group of young women (21-25 years). The results within the group of HD survivors could not be associated with the time since treatment, the age of HD survivors at diagnosis or the extent of therapy burden. CONCLUSION: Clinicians engaged in follow-up care should be sensitive to aspects of fatigue and related (emotional) symptoms in HD childhood cancer survivors and encourage their patients to seek further support if needed.
Authors: G Schellong; I Hörnig-Franz; B Rath; J Ritter; M Riepenhausen; H Kabisch; B Goldschmitt-Wuttge; P Schmidt; D Niethammer; G Gaedicke Journal: Klin Padiatr Date: 1994 Jul-Aug Impact factor: 1.349
Authors: Günther Schellong; Marianne Riepenhausen; Christian Bruch; Stefan Kotthoff; Johannes Vogt; Tobias Bölling; Karin Dieckmann; Richard Pötter; Achim Heinecke; Jürgen Brämswig; Wolfgang Dörffel Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: W Dörffel; H Lüders; U Rühl; M Albrecht; H Marciniak; R Parwaresch; R Pötter; G Schellong; E-W Schwarze; L Wickmann Journal: Klin Padiatr Date: 2003 May-Jun Impact factor: 1.349
Authors: Lonnie K Zeltzer; Qian Lu; Wendy Leisenring; Jennie C I Tsao; Christopher Recklitis; Gregory Armstrong; Ann C Mertens; Leslie L Robison; Kirsten K Ness Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-02 Impact factor: 4.254
Authors: Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett Journal: Nat Rev Dis Primers Date: 2020-07-23 Impact factor: 52.329
Authors: AnnaLynn M Williams; Sedigheh Mirzaei Salehabadi; Mengqi Xing; Nicholas S Phillips; Matthew J Ehrhardt; Rebecca Howell; Yutaka Yasui; Kevin C Oeffinger; Todd Gibson; Eric J Chow; Wendy Leisenring; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Nadine Linendoll; Tully Saunders; Rebecca Burns; Jonathan D Nyce; Kristen B Wendell; Andrew M Evens; Susan K Parsons Journal: Health Qual Life Outcomes Date: 2016-07-29 Impact factor: 3.186
Authors: Salome Christen; Katharina Roser; Renée L Mulder; Anica Ilic; Hanne C Lie; Jacqueline J Loonen; Anneli V Mellblom; Leontien C M Kremer; Melissa M Hudson; Louis S Constine; Roderick Skinner; Katrin Scheinemann; Jordan Gilleland Marchak; Gisela Michel Journal: J Cancer Surviv Date: 2020-08-25 Impact factor: 4.442